Missed the live webinar on March 18, 2026
Hathaway et al 11 showed in a single-center 2024 cohort study comparing semaglutide with non-GLP-1RA antidiabetic medications that semaglutide was associated with increased risk of NAION in 403 matched patients with type 2 diabetes (HR, 4.28 [95% CI, 1.62-11.29]) and 613 matched patients with obesity (HR, 7.64 [95% CI, 2.21-26.36]), with a temporal association observed within the first year
It mimics GLP-1 hormones to help manage food intake
3 Methamphetamine Positivity Increase Millennium Health Study Reveals Nationwide Increase in Urine Drug Test Positivity for Methamphetamine SAN DIEGO, Calif
Documented Weight Loss Outcomes with Mounjaro When considering a new medication, patients often have many questions, such as, Does Mounjaro cause hair loss